BALVERZA (erdafitinib), 3, 4, and 5mg tablets
  • Clinical Information
    Genetic Alterations in Metastatic UCFGFR and TestingMechanism of ActionStudy DesignEfficacyDosing and AdministrationSafety
  • Support and Resources
    Support for BALVERSA®ResourcesHelp Your Patients
    Find an Eye Doctor
  • Prescribing Information
  • Medical Inquiries
  • Important Safety Information
  • Información de Prescripción
  • Register for Updates
  • For US Patients
  • Contact Us
  • Find a Representative from Johnson & Johnson

Site Map

  1. Home
  2. Site Map

Home ▸

Clinical Information

Genetic Alterations in Metastatic UC ▸

FGFR and Testing ▸

Mechanism of Action ▸

Study Design ▸

Efficacy ▸

Dosing and Administration▸

Safety▸

Support and Resources

Support for BALVERSA®▸

Resources ▸

Help Your Patients Find an Eye Doctor ▸

Prescribing Information

Important Safety Information

Register for Updates ▸

Legal Notice▸

Privacy Policy ▸

Contact Us ▸

Find a Representative from Johnson & Johnson ▸

Unsubscribe ▸

Back to top